Lupin Limited, a global pharmaceutical leader, announced its first appearance in the prestigious S&P Global Sustainability Yearbook 2024, showing its strong commitment to sustainability.

With a good Corporate Sustainability Assessment (CSA) score of 69/100, Lupin is among the select companies recognised for their excellent environmental, social, and governance (ESG) practices.

The S&P Global Sustainability Yearbook 2024 is an evaluation of how companies are doing in sustainability. It assessed over 9400 companies worldwide, and only 739 made it in. Lupin did well and is in the top 95 percentile among pharmaceutical companies, showing its dedication to sustainable business practices.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of Corporate Affairs at Lupin, said, “Lupin’s inclusion in the S&P Global Sustainability Yearbook 2024 underscores our firm commitment to advancing sustainable practices within the pharmaceutical industry. This recognition reaffirms our dedication to creating long-term value for all stakeholders while fostering a healthier, more sustainable future for generations to come.”

Lupin is staying true to its mission of prioritising sustainability, making positive changes, and leaving a meaningful impact on the world.

For more investor-related news

Discover an extensive network of ESG providers here

Source: Lupin